These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 23651713)

  • 1. Renal and cardiovascular effects of irbesartan in dialysis patients--a randomized controlled trial protocol (SAFIR study).
    Peters CD; Kjærgaard KD; Jespersen B; Christensen KL; Jensen JD
    Dan Med J; 2013 Apr; 60(4):A4602. PubMed ID: 23651713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin blockade and progressive loss of kidney function in hemodialysis patients: a randomized controlled trial.
    Kjaergaard KD; Peters CD; Jespersen B; Tietze IN; Madsen JK; Pedersen BB; Novosel MK; Laursen KS; Bibby BM; Strandhave C; Jensen JD
    Am J Kidney Dis; 2014 Dec; 64(6):892-901. PubMed ID: 25011693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. No significant effect of angiotensin II receptor blockade on intermediate cardiovascular end points in hemodialysis patients.
    Peters CD; Kjaergaard KD; Jensen JD; Christensen KL; Strandhave C; Tietze IN; Novosel MK; Bibby BM; Jensen LT; Sloth E; Jespersen B
    Kidney Int; 2014 Sep; 86(3):625-37. PubMed ID: 24670413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short and Long-Term Effects of the Angiotensin II Receptor Blocker Irbesartan on Intradialytic Central Hemodynamics: A Randomized Double-Blind Placebo-Controlled One-Year Intervention Trial (the SAFIR Study).
    Peters CD; Kjaergaard KD; Jensen JD; Christensen KL; Strandhave C; Tietze IN; Novosel MK; Bibby BM; Jespersen B
    PLoS One; 2015; 10(6):e0126882. PubMed ID: 26030651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of angiotensin receptor blockade (ARB) on mortality and cardiovascular outcomes in patients with long-term haemodialysis: a randomized controlled trial.
    Iseki K; Arima H; Kohagura K; Komiya I; Ueda S; Tokuyama K; Shiohira Y; Uehara H; Toma S;
    Nephrol Dial Transplant; 2013 Jun; 28(6):1579-89. PubMed ID: 23355629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Irbesartan reduces common carotid artery intima-media thickness in hypertensive patients when compared with atenolol: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) study.
    Mörtsell D; Malmqvist K; Held C; Kahan T
    J Intern Med; 2007 May; 261(5):472-9. PubMed ID: 17444886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term effects of angiotensin II blockade with irbesartan on inflammatory markers in hemodialysis patients: A randomized double blind placebo controlled trial (SAFIR study).
    Peters CD; Kjaergaard KD; Nielsen CH; Christensen KL; Bibby BM; Jensen JD; Jespersen B
    Hemodial Int; 2017 Jan; 21(1):47-62. PubMed ID: 27346437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmacological properties and clinical efficacy of the long-active angiotensin receptor blocker (ARB) irbesartan].
    Ariyoshi Y; Mizumoto K
    Nihon Yakurigaku Zasshi; 2009 May; 133(5):275-80. PubMed ID: 19443965
    [No Abstract]   [Full Text] [Related]  

  • 9. Tissue velocity echocardiography shows early improvement in diastolic function with irbesartan and atenolol therapy in patients with hypertensive left ventricular hypertrophy. Results form the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA).
    Müller-Brunotte R; Kahan T; Malmqvist K; Ring M; Edner M
    Am J Hypertens; 2006 Sep; 19(9):927-36. PubMed ID: 16942935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-sensitivity Troponin T in hemodialysis patients: a randomized placebo-controlled sub-study investigating angiotensin-II-blockade, variation over time and associations with clinical outcome.
    Peters CD; Kjaergaard KD; Christensen KL; Bibby BM; Jespersen B; Jensen JD
    BMC Nephrol; 2020 Oct; 21(1):452. PubMed ID: 33115436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. B2 bradykinin receptor (B2BKR) polymorphism and change in left ventricular mass in response to antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial.
    Hallberg P; Lind L; Michaëlsson K; Karlsson J; Kurland L; Kahan T; Malmqvist K; Ohman KP; Nyström F; Melhus H
    J Hypertens; 2003 Mar; 21(3):621-4. PubMed ID: 12640257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term effects of irbesartan on plasma aldosterone concentration and left atrial volume in hypertensive patients.
    Masaki M; Komamura K; Goda A; Hirotani S; Otsuka M; Nakabo A; Fukui M; Fujiwara S; Sugahara M; Lee-Kawabata M; Tsujino T; Koshiba M; Masuyama T
    J Cardiol; 2014 Mar; 63(3):205-10. PubMed ID: 24060523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients: results from SECRET.
    Philipp T; Martinez F; Geiger H; Moulin B; Mourad G; Schmieder R; Lièvre M; Heemann U; Legendre C
    Nephrol Dial Transplant; 2010 Mar; 25(3):967-76. PubMed ID: 19887503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relationship between the plasma concentration of irbesartan and the antihypertensive response is disclosed by an angiotensin II type 1 receptor polymorphism: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs. Atenolol (SILVHIA) Trial.
    Kurland L; Hallberg P; Melhus H; Liljedahl U; Hashemi N; Syvänen AC; Lind L; Kahan T
    Am J Hypertens; 2008 Jul; 21(7):836-9. PubMed ID: 18464745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations.
    Pohl MA; Blumenthal S; Cordonnier DJ; De Alvaro F; Deferrari G; Eisner G; Esmatjes E; Gilbert RE; Hunsicker LG; de Faria JB; Mangili R; Moore J; Reisin E; Ritz E; Schernthaner G; Spitalewitz S; Tindall H; Rodby RA; Lewis EJ
    J Am Soc Nephrol; 2005 Oct; 16(10):3027-37. PubMed ID: 16120823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of angiotensin receptor blockade on central haemodynamics in essential hypertension: results of a randomised trial.
    Schneider MP; Delles C; Klingbeil AU; Ludwig M; Kolloch RE; Krekler M; Stumpe KO; Schmieder RE
    J Renin Angiotensin Aldosterone Syst; 2008 Mar; 9(1):49-56. PubMed ID: 18404609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective, randomized, placebo-controlled, double-blind, multicenter study of the effects of irbesartan on aortic dilatation in Marfan syndrome (AIMS trial): study protocol.
    Mullen MJ; Flather MD; Jin XY; Newman WG; Erdem G; Gaze D; Valencia O; Banya W; Foley CE; Child A
    Trials; 2013 Dec; 14():408. PubMed ID: 24289736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimated GFR decline as a surrogate end point for kidney failure: a post hoc analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) study and Irbesartan Diabetic Nephropathy Trial (IDNT).
    Lambers Heerspink HJ; Weldegiorgis M; Inker LA; Gansevoort R; Parving HH; Dwyer JP; Mondal H; Coresh J; Greene T; Levey AS; de Zeeuw D
    Am J Kidney Dis; 2014 Feb; 63(2):244-50. PubMed ID: 24210590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design.
    Carson P; Massie BM; McKelvie R; McMurray J; Komajda M; Zile M; Ptaszynska A; Frangin G;
    J Card Fail; 2005 Oct; 11(8):576-85. PubMed ID: 16230259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Telmisartan reduces mortality and left ventricular hypertrophy with sympathoinhibition in rats with hypertension and heart failure.
    Kishi T; Hirooka Y; Sunagawa K
    Am J Hypertens; 2014 Feb; 27(2):260-7. PubMed ID: 24096926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.